ReviewPublic health challenges2026
Mpox Outbreak in the East Africa Region: Current Status, Containment Measures, Challenges, and Future Direction.
Review in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mpox Outbreak in the East Africa Region: Current Status, Containment Measures, Challenges, and Future Direction.Public health challenges · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, the World Health Organization declared Mpox outbreak a Public Health Emergency of International Concern. The epicenter of this outbreak was the Democratic Republic of Congo (DRC), which is a member of the East African Community (EAC). The majority of EAC countries reported Mpox cases and associated deaths. Mpox outbreak negatively affected EAC member states but triggered the strengthening of diagnostic and surveillance capacity. This review assessed the status, containment measures, challenges, and future directions of Mpox in the EAC. As of July 27, 2025, the DRC was the top country in the world with Mpox with 28,165 cases and 69 deaths, followed by Uganda, Burundi, Kenya, Rwanda, Tanzania, and South Sudan with 7648 cases and 48 deaths, 4231 cases and one death, 281 cases and five deaths, 124 cases, 111 cases, and 17 cases, respectively. Rwanda, Tanzania, and South Sudan have not recorded any death associated with Mpox. The DRC, Uganda, and Burundi experienced extensive transmission rates, whereas Kenya and Uganda had higher case fatality rates of 1.78 and 0.63, respectively. Containment measures in EAC countries included enhanced surveillance, public awareness campaigns, training on infection prevention and control, and vaccination. Of the 801,000 Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine doses administered, over 73% were administered in the DRC. Challenges, including inadequate healthcare infrastructure and misinformation, affected Mpox control measures. This study underlines the need for a joint regional strategy to strengthen outbreak preparedness and ensure equitable access to resources to build resilience against emerging infectious diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.